Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer predict dramatic clinical responses to tyrosine kinase inhibitor (TKI) treatment. The conclusion on EGFR mutation-specific antibodies by immunohistochemistry (IHC) is not consistent. We evaluated the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ruiguang, Li, Yan, Nie, Xiu, Dong, Xiaorong, Wu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723025/
https://www.ncbi.nlm.nih.gov/pubmed/26848271
http://dx.doi.org/10.2147/OTT.S95785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723025/
https://www.ncbi.nlm.nih.gov/pubmed/26848271
http://dx.doi.org/10.2147/OTT.S95785

Ejemplares similares